Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873: 188314. https://doi.org/10.1016/j.bbcan.2019.188314.
Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57: 100770. https://doi.org/10.1016/j.drup.2021.100770.
Soerjomataram I, Oomen D, Lemmens V, Oenema A, Benetou V, Trichopoulou A, Coebergh JW, Barendregt J, de Vries E. Increased consumption of fruit and vegetables and future cancer incidence in selected European countries. Eur J Cancer. 2010;46:2563–80. https://doi.org/10.1016/j.ejca.2010.07.026.
Garg P, Garg R, Horne D, Awasthi S, Salgia R, Singhal SS. Prognostic significance of natural products against multidrug tumor resistance. Cancer Lett. 2023;557: 216079. https://doi.org/10.1016/j.canlet.2023.216079.
Wang QL, Zhang PX, Shen R, Xu M, Han L, Shi X, et al. Determination of arbutin in vitro and in vivo by LC-MS/MS: Pre-clinical evaluation of natural product arbutin for its early medicinal properties. J Ethnopharmacol. 2024;330: 118232. https://doi.org/10.1016/j.jep.2024.118232.
Sharma A, Kakkar A, Khanna M, Devi S. Arbutin’s potential in neuroprotection: a promising role in mitigating neurodegenerative diseases. Curr Drug Res Rev. 2024. https://doi.org/10.2174/0125899775298987240528050110.
Qin D, Liu J, Guo W, Ju T, Fu S, Liu D, et al. Arbutin alleviates intestinal colitis by regulating neutrophil extracellular traps formation and microbiota composition. Phytomedicine. 2024;130: 155741. https://doi.org/10.1016/j.phymed.2024.155741.
Birdal O, Ferah Okkay I, Okkay U, Bayram C, Mokthare B, Ertugrul MS, et al. Protective effects of arbutin against doxorubicin-induced cardiac damage. Mol Biol Rep. 2024;51:532. https://doi.org/10.1007/s11033-024-09488-4.
Sial NT, Malik A, Iqbal U, Rehman M. Arbutin attenuates CFA-induced arthritis by modulating expression levels of 5-LOX, NF-κB, IL-17, PGE-2 and TNF-α. Inflammopharmacology. 2024;32:2377–94. https://doi.org/10.1007/s10787-024-01480-5.
Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 1997;91:209–19. https://doi.org/10.1016/s0092-8674(00)80403-1.
Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14:233–47. https://doi.org/10.1038/nrc3700.
Article PubMed PubMed Central Google Scholar
Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM. Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol. 2016;36:18–32. https://doi.org/10.1016/j.semcancer.2015.09.008.
Yan L, Lin M, Pan S, Assaraf YG, Wang ZW, Zhu X. Emerging roles of F-box proteins in cancer drug resistance. Drug Resist Updat. 2020;49: 100673. https://doi.org/10.1016/j.drup.2019.100673.
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C, Shen A, Wang Y, Li C, Yuan Q, Chen H, Cheng C, He S. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol. 2013;44:365–73. https://doi.org/10.1016/j.humpath.2012.03.030.
Liu P, Wang X, Pan L, Han B, He Z. Prognostic significance and immunological role of FBXO5 in human cancers: a systematic pan-cancer analysis. Front Immunol. 2022;13: 901784. https://doi.org/10.3389/fimmu.2022.901784.
Article PubMed PubMed Central Google Scholar
Heo J, Eki R, Abbas T. Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol. 2016;36:33–51. https://doi.org/10.1016/j.semcancer.2015.09.015.
Xu C, Luo L, Yu Y, Zhang Z, Zhang Y, Li H, Cheng Y, Qin H, Zhang X, Ma H, Li Y. Screening therapeutic targets of ribavirin in hepatocellular carcinoma. Oncol Lett. 2018;15:9625–32. https://doi.org/10.3892/ol.2018.8552.
Article PubMed PubMed Central Google Scholar
Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022–7. https://doi.org/10.1097/SLA.0b013e31827da749.
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203–22. https://doi.org/10.1038/s41575-022-00704-9.
Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19:326–38. https://doi.org/10.1038/s41568-019-0143-7.
Di Fiore B, Pines J. Emi1 is needed to couple DNA replication with mitosis but does not regulate activation of the mitotic APC/C. J Cell Biol. 2007;177:425–37. https://doi.org/10.1083/jcb.200611166.
Article PubMed PubMed Central Google Scholar
Machida YJ, Dutta A. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes Dev. 2007;21:184–94. https://doi.org/10.1101/gad.1495007.
Article PubMed PubMed Central Google Scholar
Gütgemann I, Lehman NL, Jackson PK, Longacre TA. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 2008;21:445–54. https://doi.org/10.1038/modpathol.3801022.
Min KW, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, Joo HJ, Park IA, An HJ, Suh KS, Oh HK, Yoo CW, Kim MJ, Chang HK, Jun SY, Yoon HK, Chang ED, Kim DW, Kim I, Gynecologic Pathology Study Group of the Korean Society of Pathologists. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 2013;32:3-14. https://doi.org/10.1097/PGP.0b013e31825554e9
Lehman NL, Verschuren EW, Hsu JY, Cherry AM, Jackson PK. Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells. Cell Cycle. 2006;5:1569–73. https://doi.org/10.4161/cc.5.14.2925.
Chen JY, Wang MC, Hung WC. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J Cell Physiol. 2011;226:407–13. https://doi.org/10.1002/jcp.22346.
Xie H, Kang Y, Wang S, Zheng P, Chen Z, Roy S, Zhao C. E2f5 is a versatile transcriptional activator required for spermatogenesis and multiciliated cell differentiation in zebrafish. PLoS Genet. 2020;16: e1008655. https://doi.org/10.1371/journal.pgen.1008655.
Article PubMed PubMed Central Google Scholar
Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, Miao H, Cui X, Wei S, Liu W, Chen S, Wang J. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci. 2021;17:3608–21. https://doi.org/10.7150/ijbs.64003.
Article PubMed PubMed Central Google Scholar
Kassab A, Gupta I, Moustafa AA. Role of E2F transcription factor in oral cancer: recent insight and advancements. Semin Cancer Biol. 2023;92:28–41. https://doi.org/10.1016/j.semcancer.2023.03.004.
Zhang J, Zhang G, Wang K, Cui F, Yang H, Jiao Z. Exploring the role of FBXO5 in gastric cancer. Mol Cell Probes. 2023;69: 101915. https://doi.org/10.1016/j.mcp.2023.101915.
留言 (0)